Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Predictive value of lung function results for sleep-disordered breathing in children with sickle cell disease: A multicenter cross-sectional study

Ammar Alishlash, Anis Nourani, A K M Fazlur Rahman et al. Nov 03, 2025 pp. 2943-2943 10.1182/blood-2025-2943

Abstract Background: Lung function abnormalities and sleep-disordered breathing are more prevalent in children with sickle cell disease (SCD...

Targeting the ARHGAP18/PI3K/AKT axis with vincristine and cytarabine synergistically suppresses senescence and induces apoptosis in AML

Haotian Yan, Wenjie Dai, Qing Zhang et al. Nov 03, 2025 pp. 6806-6806 10.1182/blood-2025-6806

Abstract Background: Cytarabine-based regimens remain the backbone of AML induction and consolidation therapy, yet drug resistance and relap...

Castleman disease as a spectrum: Characterization of novel subtypes using data from the spanish GELTAMO registry

Gianfranco Lapietra, Aleix Mendez, Xavier Cintas et al. Nov 03, 2025 pp. 1233-1233 10.1182/blood-2025-1233

Abstract Introduction Castleman disease (CD) unrelated to HHV-8 or POEMS syndrome comprises a heterogenous group of disorders characterized...

Outcomes of pregnancies in sickle cell patients treated with hydroxyurea : Findings from the escort-HU cohort studies

Anoosha Habibi, Maryse Etienne-Julan, Maria Dimopoulou et al. Nov 03, 2025 pp. 2-2 10.1182/blood-2025-2

Abstract Background: Hydroxyurea (HU) is a widely used therapy for sickle cell disease (SCD), reducing the frequency of vaso-occlusive crise...

Treatment-free remission outcomes in pediatric chronic myeloid leukemia: Second-generation TKIs vs. Imatinib–a real-world multicenter study from China

Huifang Zhao, Yu Zhu, Na Xu et al. Nov 03, 2025 pp. 3786-3786 10.1182/blood-2025-3786

Abstract Background Studies have demonstrated that a subset of adult chronic myeloid leukemia (CML) patients achieving deep molecular respons...

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Carla Casulo, Hongli Li, Alex Herrera et al. Nov 03, 2025 pp. 154-154 10.1182/blood-2025-154

Abstract Background The most widely used prognostication tool in classical Hodgkin lymphoma (cHL) historically has been the International Pr...

Preclinical evaluation of SPK-8011QQ, an adeno-associated virus gene therapy for people with hemophilia A leveraging the dirloctocogene samoparvovec platform encoding an activated Protein C-resistant B-domain deleted factor VIII

Nina Frey, Nicolas Receveur, Michel Enderlin-Paput et al. Nov 03, 2025 pp. 1068-1068 10.1182/blood-2025-1068

Abstract Background: Gene therapies for hemophilia A (HA) offer the potential for durable factor (F)VIII expression as a curative treatment...

B-like natural killer cells related to the epstein-barr virus infection present an adaptive immune phenotype and stronger killing activity in lymphomas

Yuanbin Song, Yang Liang, Chenfei Liu et al. Nov 03, 2025 pp. 1769-1769 10.1182/blood-2025-1769

Abstract Background: Natural killer (NK) cells play a profound role in the immune system, contributing to antitumor and...

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Fabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi et al. Nov 03, 2025 pp. 6278-6278 10.1182/blood-2025-6278

Abstract Background Chimeric antigen receptor (CAR) T-cell therapy is a valuable treatment option for patients with aggressive B-cell lympho...

Rare but not forgotten, a case of evan's syndrome.

Rachel Tatro, Abdul Wahab, Jonathan Piccolo et al. Nov 03, 2025 pp. 6518-6518 10.1182/blood-2025-6518

Abstract A 46-year-old woman with a history of sickle cell trait presented with several weeks of fatigue, nausea, vomiting, and shortness of...

Evaluation of greatwall kinase inhibition as a potential therapeutic strategy in CLL and DLBCL.

Elaina Pasangha, Lauren Stott, Iona Ashworth et al. Nov 03, 2025 pp. 7846-7846 10.1182/blood-2025-7846

Abstract Background: Greatwall (GWL), also known as MASTL (microtubule-associated serine/threonine kinase-like), is an enzyme active during...

It's not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib

Massimiliano Bonifacio, Alda Strazimiri, Giuseppe Carli et al. Nov 03, 2025 pp. 3820-3820 10.1182/blood-2025-3820

Abstract Background. Ruxolitinib (RUX), the first JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF), has significantly impro...

Endogenous and therapeutic transport of activated protein c across the blood-retina barrier protects the retina

Sarina Levy-Mendelovich, Yael nisgav, Rima Dardik et al. Nov 03, 2025 pp. 15-15 10.1182/blood-2025-15

Abstract Introduction: Protein C (PC) deficiency is a devastating thrombophilia. Its most striking non-thrombotic consequences involve the e...

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Michelle Nwachukwu, Wei-Ying Jen, Jeremy Ramdial et al. Nov 03, 2025 pp. 6975-6975 10.1182/blood-2025-6975

Abstract Background: Despite improvements in overall survival (OS) after allogeneic stem cell transplant (alloSCT) in patients with acute my...

Presenting features, treatment patterns and predictors of outcomes in AL amyloidosis at a tertirary care cancer centre

Aditya Nair, Dhyey Mishra, Archit Shirpurkar et al. Nov 03, 2025 pp. 7501-7501 10.1182/blood-2025-7501

Abstract Introduction Light Chain (AL) amyloidosis is the most common form of systemic amyloidosis, characterized by the deposition of misfo...

The international diamond blackfan anemia syndrome cancer consortium: Preliminary results

Adrianna Vlachos, Marije Bartels, Polyxeni Delaporta et al. Nov 03, 2025 pp. 4996-4996 10.1182/blood-2025-4996

Abstract Background: Diamond Blackfan anemia (DBA) syndrome is an inherited bone marrow failure syndrome characterized by red cell aplasia,...

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Dok Hyun Yoon, Hyungwoo Cho, Jaewon Hyung et al. Nov 03, 2025 pp. 2399-2399 10.1182/blood-2025-2399

Abstract Background CAR T cell therapy has demonstrated improved outcomes for patients with relapsed/refractory diffuse large B-cell lymphom...

Rapid transformation from JAK2-positive PMF to acute leukemia: Therapeutic challenges and rare DIC in an aggressive disease course

Sindhu Chadalawada, Malik Abubakar, Lewis Steinberg Nov 03, 2025 pp. 7284-7284 10.1182/blood-2025-7284

Abstract Background: Primary myelofibrosis (PMF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by pro...

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Annie Xiao, Jarrod Smith, Jomel Meeko Manzano et al. Nov 03, 2025 pp. 6294-6294 10.1182/blood-2025-6294

Abstract Introduction Bendamustine (benda) has prolonged lymphotoxic effects, and recent benda exposure prior to apheresis negatively impact...

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Iva Hamova, Prokop Vodička, Adriana Velasova et al. Nov 03, 2025 pp. 1763-1763 10.1182/blood-2025-1763

Abstract Introduction. Circulating tumor DNA (ctDNA) was identified as a powerful biomarker for treatment response evaluation and outcome pr...

Early reduction of BCR-ABL at 3 months predicts deeper molecular remission in pediatric CML

Xingchen Wang, Wenbin An, Bang Zhang et al. Nov 03, 2025 pp. 3783-3783 10.1182/blood-2025-3783

Abstract Background: Chronic myeloid leukemia (CML) is extremely rare in pediatric populations, and clinical features and therapeutic respons...

Characterizing thrombosis in acute promyelocytic leukemia: Real-world insights from the middle east

Hawraa Shawaylia, Rafal Alshebly, Anil Yousaf et al. Nov 03, 2025 pp. 6612-6612 10.1182/blood-2025-6612

Abstract Background: During the early phase of acute promyelocytic leukemia (APL), patients face a high risk of coagulopathy, predominantly...

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

Aleksandra Filipovic, Amir Fathi, Noah Merin et al. Nov 03, 2025 pp. 1648-1648 10.1182/blood-2025-1648

Abstract Background: LYT-200 is a fully human IgG4 monoclonal antibody targeting galectin-9 (Gal-9), a key mediator of oncogenesis and immun...

The role of ENO1 and chidamide in PTCL-NOS

Mingxi Tian, Jiao Liu, Xuejiao Gu et al. Nov 03, 2025 pp. 7081-7081 10.1182/blood-2025-7081

Abstract Enolase (ENO1) is a key enzyme involved in glycolysis and plays an important role in various types of cancer. This study explored t...

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky et al. Nov 03, 2025 pp. 2220-2220 10.1182/blood-2025-2220

Abstract Introduction: Accurate risk stratification in multiple myeloma (MM) is essential to guide treatment decisions and improve outcomes,...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page